Skip to main content
COVID-19 Notice: 

NovoSeven® RT helps the broadest range of patientsa with bleeding disorders as compared to FEIBA® and Obizur®.1-3

aIndicated for bleed control and surgery in 4 bleeding disorders:
CHAwI or CHBwI, AH, CFVIId, and GT.1

Image

Double click to edit

CHwI=congenital hemophilia with inhibitors; CHAwI=congenital hemophilia A with inhibitors; CHBwI=congenital hemophilia B with inhibitors;
AH=acquired hemophilia; CFVIId=congenital factor VII deficiency; GT=Glanzmann’s thrombasthenia.

Experience you can count on.

NovoSeven® RT helps the broadest range of patientsa with bleeding disorders as compared to FEIBA® and Obizur®.1-3

aIndicated for bleed control and surgery in 4 bleeding disorders: CHAwI or CHBwI, AH, CFVIId, and GT.1

CHwI=congenital hemophilia with inhibitors;
CHAwI=congenital hemophilia A with inhibitors;
CHBwI=congenital hemophilia B with inhibitors;
AH=acquired hemophilia; CFVIId=congenital factor VII deficiency; GT=Glanzmann’s thrombasthenia.

Featured professional education.

Featured professional education.

The most used rFVIIa in hospitals.1,4

NovoSeven® RT is effective across four indications — congenital hemophilia A and B with inhibitors, acquired hemophilia, factor VII deficiency, and Glanzmann’s thrombasthenia.1 Explore information and clinical pathways for treating bleeding episodes and for perioperative management of these indications in the hospital.

Use our convenient dosing calculator.

With our dosing calculator, you can quickly determine the recommended NovoSeven® RT dose for your patient, plus the number of vials required.
 

Support for your patients.

Novo Nordisk is there for every step in a patient's journey. Our programs include financial assistance for accessing treatment, scholarship opportunities, career and empowerment coaching, and more.

Contact a representative.

Have questions about using or accessing NovoSeven® RT? Our Hemophilia Therapy Managers (HTMs) and Hemophilia Institutional Account Managers (HIAMs) are here to help. Find a local representative to get the information you and your patients need.

Selected Important Safety Information

WARNING: THROMBOSIS

  • Serious arterial and venous thrombotic events following administration of NovoSeven® RT have been reported
  • Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven® RT
  • Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis

Warnings and Precautions

  • Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance
  • Patients with congenital hemophilia receiving concomitant treatment with aPCCs (activated prothrombin complex concentrates), older patients particularly with acquired hemophilia and receiving other hemostatic agents, and patients with a history of cardiac and vascular disease may have an increased risk of developing thrombotic events

Indications and Usage

NovoSeven® RT (coagulation Factor VIIa, recombinant) is a coagulation factor indicated for:

  • Treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets
  • Treatment of bleeding episodes and perioperative management in adults with acquired hemophilia

Important Safety Information

WARNING: THROMBOSIS

  • Serious arterial and venous thrombotic events following administration of NovoSeven® RT have been reported
  • Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven® RT
  • Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis

Warnings and Precautions

  • Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance
  • Patients with congenital hemophilia receiving concomitant treatment with aPCCs (activated prothrombin complex concentrates), older patients particularly with acquired hemophilia and receiving other hemostatic agents, and patients with a history of cardiac and vascular disease may have an increased risk of developing thrombotic events
  • Hypersensitivity reactions, including anaphylaxis, can occur with NovoSeven® RT. Patients with a known hypersensitivity to mouse, hamster, or bovine proteins may be at a higher risk of hypersensitivity reactions. Discontinue infusion and administer appropriate treatment when hypersensitivity reactions occur
  • Factor VII deficient patients should be monitored for prothrombin time (PT) and factor VII coagulant activity (FVII:C). If FVII:C fails to reach the expected level, or PT is not corrected, or bleeding is not controlled after treatment with the recommended doses, antibody formation may be suspected and analysis for antibodies should be performed
  • Laboratory coagulation parameters (PT/INR, aPTT, FVII:C) have shown no direct correlation to achieving hemostasis

Adverse Reactions

  • The most common and serious adverse reactions in clinical trials are thrombotic events. Thrombotic adverse reactions following the administration of NovoSeven® RT in clinical trials occurred in 4% of patients with acquired hemophilia and 0.2% of bleeding episodes in patients with congenital hemophilia

Drug Interactions

  • Thrombosis may occur if NovoSeven® RT is administered concomitantly with Coagulation Factor XIII

Please click here for Prescribing Information

Reference:

  1. NovoSeven RT [package insert]. Plainsboro, NJ: Novo Nordisk Inc; 2020.
  2. FEIBA [package insert]. Westlake Village, CA: Baxter Healthcare Corporation; 2018.
  3. Obizur [package insert]. Westlake Village, CA: Baxter Healthcare Corporation; 2020
  4. Data on file as of 2019. Novo Nordisk Inc; Plainsboro, NJ.